Tirzepatide vs AOD-9604

Tirzepatide wins for raw appetite suppression, total fat-loss magnitude (15–21% per year), metabolic syndrome management, and monotherapy cuts where maximal reduction is the goal. It's the only pharmaceutical-level tool here, with GLP-1/GIP agonism that actually moves the needle—hard, fast, and predictable—at even microdose tiers.

AOD-9604 wins for zero-side effect lipolysis, gentle and subtle recomposition with no appetite, GI, or lean-mass cost, legal gray-market sourcing, and seamless stacking (especially alongside GH, secretagogues, or GLP-1s themselves). It's a 'precision modulator,' not a sledgehammer—perfect for polishing off stubborn depots, or for users who want visible fat loss with zero systemic impact.

Pick Tirzepatide if:

• You need aggressive, pharmaceutical-grade fat loss beyond the reach of any natural or peptide stack
• You want robust appetite suppression as the main driver (e.g., contest prep, deep cut, or cutting while running AAS)
• You're managing prediabetes, insulin resistance, or other glycemic concerns along with fat loss
• You're fine with injectables and titrating doses to minimize GI issues
• Maximizing efficiency in large or rapid weight loss phases is the priority

Pick AOD-9604 if:

• You want to selectively target stubborn fat without appetite or muscle-mass tradeoff
• You're already using GH, peptides, or a GLP-1 and want an add-on for more nuanced fat loss
• You prefer a protocol with effectively no side effects and no impact on glucose or hormone status
• You're a female user avoiding hormonal manipulation and want a peptide both sexes can run cleanly
• Mild, sustainable, stack-friendly recomposition is the main goal, not dramatic weight reduction